AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Lay Description
Objectives
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Category
- Heart, Vascular and Blood
- IRB Number
- 20180178HU
- NCT Number
- NCT03192215
Eligibility
- Eligible Ages
- Over 45 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Sarah Martinez
210-450-0569
martinezs23@uthscsa.edu
Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu
Principal Investigator
Reza Behrouz